In the past week, RDHL stock has gone down by -3.14%, with a monthly decline of -48.30% and a quarterly plunge of -62.15%. The volatility ratio for the week is 12.43%, and the volatility levels for the last 30 days are 12.57% for Redhill Biopharma Ltd. ADR The simple moving average for the past 20 days is -22.91% for RDHL’s stock, with a -66.00% simple moving average for the past 200 days.
Is It Worth Investing in Redhill Biopharma Ltd. ADR (NASDAQ: RDHL) Right Now?
The 36-month beta value for RDHL is at 4.42. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RDHL is 1.27M, and currently, shorts hold a 2.68% of that float. The average trading volume for RDHL on March 18, 2025 was 70.36K shares.
RDHL) stock’s latest price update
The stock price of Redhill Biopharma Ltd. ADR (NASDAQ: RDHL) has plunged by -10.22 when compared to previous closing price of 3.01, but the company has seen a -3.14% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-18 that RedHill plans to submit UK MAA 1 for Talicia for H. pylori infection, using MHRA’s 2 new fast-track approval process, referencing FDA approval, with potential UK approval in Q4/25 Listed by ACG 3 Clinical Guideline as a first-line option, Talicia is the leading branded H.
Analysts’ Opinion of RDHL
Many brokerage firms have already submitted their reports for RDHL stocks, with Cantor Fitzgerald repeating the rating for RDHL by listing it as a “Overweight.” The predicted price for RDHL in the upcoming period, according to Cantor Fitzgerald is $22 based on the research report published on August 31, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see RDHL reach a price target of $23. The rating they have provided for RDHL stocks is “Buy” according to the report published on May 18th, 2021.
RDHL Trading at -45.46% from the 50-Day Moving Average
After a stumble in the market that brought RDHL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.67% of loss for the given period.
Volatility was left at 12.57%, however, over the last 30 days, the volatility rate increased by 12.43%, as shares sank -49.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -58.59% lower at present.
During the last 5 trading sessions, RDHL fell by -5.02%, which changed the moving average for the period of 200-days by -76.70% in comparison to the 20-day moving average, which settled at $3.50. In addition, Redhill Biopharma Ltd. ADR saw -56.48% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RDHL
Current profitability levels for the company are sitting at:
- 1.94 for the present operating margin
- 0.47 for the gross margin
The net margin for Redhill Biopharma Ltd. ADR stands at 3.67. The total capital return value is set at 3.32.
Based on Redhill Biopharma Ltd. ADR (RDHL), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -30.54. The debt to equity ratio resting at 0.57. The interest coverage ratio of the stock is 34.42.
Currently, EBITDA for the company is 26.31 million with net debt to EBITDA at -0.17. When we switch over and look at the enterprise to sales, we see a ratio of -0.67. The receivables turnover for the company is 1.98for trailing twelve months and the total asset turnover is 0.28.
Conclusion
In conclusion, Redhill Biopharma Ltd. ADR (RDHL) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
